Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AEMD 
Aethlon Medical Inc (AEMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: AEMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.38
1 Year Target Price $12.38
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.09% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.24M USD | Price to earnings Ratio - | 1Y Target Price 12.38 |
Price to earnings Ratio - | 1Y Target Price 12.38 | ||
Volume (30-day avg) 1 | Beta 1.63 | 52 Weeks Range 4.02 - 84.40 | Updated Date 11/6/2025 |
52 Weeks Range 4.02 - 84.40 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -66.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -63.64% | Return on Equity (TTM) -207.29% |
Valuation
Trailing PE - | Forward PE 0.21 | Enterprise Value 2121238 | Price to Sales(TTM) 2.37 |
Enterprise Value 2121238 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 761210 | Shares Floating 258372 |
Shares Outstanding 761210 | Shares Floating 258372 | ||
Percent Insiders 3.39 | Percent Institutions 5.27 |
Upturn AI SWOT
Aethlon Medical Inc
Company Overview
History and Background
Aethlon Medical, Inc. is a medical technology company focused on developing therapeutic technologies to combat life-threatening diseases. Founded in 1991, Aethlon has focused on its Hemopurifieru00ae technology to address infectious diseases and cancer.
Core Business Areas
- Hemopurifieru00ae Development: Aethlon's core business revolves around the development and commercialization of the Hemopurifieru00ae, a device designed to remove viruses and exosomes from the bloodstream.
Leadership and Structure
The leadership team consists of experienced professionals in medical technology and business. The organizational structure is typical of a small, publicly traded company, with a focus on research and development, clinical trials, and regulatory approval.
Top Products and Market Share
Key Offerings
- Hemopurifieru00ae: The Hemopurifieru00ae is a medical device designed to remove viruses and cancer-promoting exosomes from the blood. As of now, it does not have significant market share. Potential competitors include companies developing similar blood purification technologies, though the specific competitive landscape is evolving pending regulatory approval and market adoption. It is approved for use in Expanded Access Programs and has been studied in various clinical trials, but lacks widespread commercialization.
Market Dynamics
Industry Overview
The industry includes medical devices focusing on blood purification and therapeutic apheresis. This market is characterized by technological innovation and regulatory scrutiny.
Positioning
Aethlon is positioned as an innovative player in the blood purification space, focusing on applications in infectious diseases and oncology. Its competitive advantage lies in the unique mechanism of action of the Hemopurifieru00ae.
Total Addressable Market (TAM)
The TAM for blood purification devices is significant and growing. Aethlon's position within this TAM depends on the successful commercialization of the Hemopurifieru00ae and securing regulatory approvals for specific indications.
Upturn SWOT Analysis
Strengths
- Innovative Hemopurifieru00ae technology
- Potential applications in multiple disease areas
- Experienced management team
Weaknesses
- Limited commercialization to date
- Dependence on regulatory approvals
- Small company with limited resources
Opportunities
- Expanding applications of Hemopurifieru00ae in oncology and infectious diseases
- Partnerships with larger pharmaceutical or medical device companies
- Government funding for research and development
Threats
- Regulatory hurdles
- Competition from established medical device companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Baxter International Inc (BAX)
- Asahi Kasei Corporation (3407.T)
- Fresenius Medical Care AG & Co. KGaA (FMS)
Competitive Landscape
Aethlon faces competition from established medical device companies with greater resources. Its advantage lies in its innovative technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in research and development activities.
Future Projections: Future growth is highly dependent on the successful commercialization of the Hemopurifieru00ae.
Recent Initiatives: Recent initiatives include clinical trials for cancer and infectious disease applications.
Summary
Aethlon Medical is a high-risk, high-reward company focused on a novel blood purification technology. Its success hinges on positive clinical trial outcomes and regulatory approvals for its Hemopurifieru00ae. The company needs to secure funding and partnerships to advance commercialization. Potential investors should carefully consider the risks and potential rewards associated with this developmental-stage medical device company.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC), press releases, analyst reports, and third-party industry research.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is an estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aethlon Medical Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2001-01-02 | CEO, CFO, Chief Accounting Officer, Secretary & Director Mr. James B. Frakes M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 9 | Website https://www.aethlonmedical.com |
Full time employees 9 | Website https://www.aethlonmedical.com | ||
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.